TC
HRTX icon

Tejara Capital’s Heron Therapeutics HRTX Stock Holding History

Tejara Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
6,510,795
+174,040
+3% +$140K 1.14% 28
2026
Q1 		$5.07M Buy
6,336,755
+1,205,329
+23% +$1.4M 1.67% 16
2025
Q4 		$6.67M Buy
5,131,426
+541,711
+12% +$669K 1.57% 12
2025
Q3 		$5.78M Buy
4,589,715
+72,300
+2% +$115K 3.02% 10
2025
Q2 		$9.35M Sell
4,517,415
-59,992
-1% -$123K 4.34% 3
2025
Q1 		$10.1M Sell
4,577,407
-84,140
-2% -$163K 3.89% 3
2024
Q4 		$7.13M Sell
4,661,547
-644,269
-12% -$1.04M 4.67% 8
2024
Q3 		$10.6M Buy
5,305,816
+1,117,956
+27% +$2.67M 5.03% 4
2024
Q2 		$14.7M Sell
4,187,860
-223,707
-5% -$687K 5.33% 2
2024
Q1 		$12.2M Sell
4,411,567
-863,669
-16% -$2.17M 4.49% 3
2023
Q4 		$8.97M Buy
5,275,236
+3,165,555
+150% +$3.49M 3.76% 9
2023
Q3 		$2.17M Buy
2,109,681
+469,548
+29% +$668K 1.23% 25
2023
Q2 		$1.9M Sell
1,640,133
-27,386
-2% -$48.8K 0.94% 31
2023
Q1 		$2.52M Buy
1,667,519
+1,173,900
+238% +$2.94M 1.29% 26
2022
Q4 		$1.23M Buy
+493,619
New +$1.59M 0.71% 39

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tejara Capital's HRTX Position: Q2 2026 in Review

Tejara Capital increased its Heron Therapeutics (HRTX) stake by 2.7% in Q2 2026, buying an estimated $140K and bringing the position to 6,510,795 shares worth $2.78M. The position accounts for 1.14% of the portfolio, ranked #28.

Tejara Capital first reported a position in HRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.7M in Q2 2024. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Tejara Capital held 6,510,795 shares of Heron Therapeutics worth $2.78M as of Q2 2026.
  • Tejara Capital bought 174,040 Heron Therapeutics shares in Q2 2026, an estimated $140K.
  • Heron Therapeutics made up 1.14% of Tejara Capital's portfolio in Q2 2026, its #28 holding.
  • Tejara Capital first reported a position in Heron Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Tejara Capital's Heron Therapeutics position peaked at $14.7M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.